Champions Oncology, Inc. (CSBR) vs Hyperfine, Inc. (HYPR)
A side-by-side comparison of Champions Oncology, Inc. and Hyperfine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CSBR
Champions Oncology, Inc.
$5.01HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
HYPR
Hyperfine, Inc.
$0.87HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CSBR vs HYPR
growth of $100 · dividends reinvested · last 6yCSBR -56.3% (-12.9%/yr)HYPR -91.2% (-33.3%/yr)CSBR compounded faster over this window
CSBR HYPR
CSBR vs HYPR: by the numbers
- •HYPR is the larger company ($73M vs $70M market cap).
- •Both run net losses; CSBR's is the smaller (-1.87% vs -210.75% net margin).
- •HYPR grew revenue faster over the past five years (77.73% vs 7.25% CAGR).
Metrics side by side
Valuation
| Metric | CSBR | HYPR |
|---|---|---|
| Forward P/E | 50.10 | N/A |
| P/S ratio | 1.15 | 4.43 |
| P/B ratio | 17.88 | 1.99 |
| EV / EBITDA | 261.92 | N/A |
Profitability
| Metric | CSBR | HYPR |
|---|---|---|
| Gross margin | 49.30% | 51.41% |
| Operating margin | -1.72% | -273.43% |
| Net margin | -1.87% | -210.75% |
| ROE | -29.15% | -94.81% |
| ROIC | -6.75% | -62.98% |
Growth (annualized)
| Metric | CSBR | HYPR |
|---|---|---|
| Revenue CAGR (5Y) | 7.25% | 77.73% |
| Total return CAGR (5Y) | -13.07% | -38.34% |
Frequently asked
- Which has grown faster, CSBR or HYPR?
- Over the past five years, HYPR grew revenue faster — CSBR at a 7.25% CAGR versus HYPR at 77.73%.
- How have CSBR and HYPR total returns compared?
- Over the past 5 years, CSBR delivered -13.07% and HYPR delivered -38.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Champions Oncology ROEHyperfine ROEChampions Oncology operating marginHyperfine operating marginChampions Oncology revenue growthHyperfine revenue growthChampions Oncology free cash flowHyperfine free cash flow
Champions Oncology & Hyperfine appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.